The purpose of our research is the investigation of mulitmodal treatment in adult patients with neoplastic disease in collaboration with other member institutions in the CALGB. Walter Reed Army Medical Center (WRAMC) has been an active member of CALGB for 28 years. WRAMC's participation has been under the guidance of Dr. Raymond Weiss for 6 years. In that 6 years there has been a steady rise in patient accrual to a level of nearly 125/year. There has been steady scientific input with chairmanship by WRAMC investigators of phase II studies and major involvement in the leadership of the Testicular Cancer Intergroup and the Head and Neck Cancer Intergroup Studies. In addition, there has been major input administratively with Dr. Weiss' chairmanship of the Data Audit Committee. Dr. Weiss is also serving a 4 year term as a member of the Executive Committee. Dr. Weiss is also a member of the Breast Cancer and Chemotherapy Core Committees, and Dr. Diehl is a member of the Lymphoma Core Committee. The quality of data collection at WRAMC has been rated as """"""""excellent"""""""" by the Standards and Peer Review Committee, and the data delinquency rate is very low. WRAMC accrues many patients to leukemia studies and has accrued heavily to the leukemia companison studies. Dr. Surana had some problems with quality initially in 1985, but these have been corrected and peer review of WRAMC cytogenetic quality has now been favorable. Radiation Oncology input to CALGB studies has been only on a service basis, but data are submitted on time, and there have been no major and very few minor deviations from protocol-dictated treatment. Dr. Weiss' major interests are breast cancer and new drug studies. He will continue to make contributions to CALGB in this area. The WRAMC investigators enthusiatically participate in CALGB, although they will not be Group leaders in new scientific ventures. Protocol accrual and data collection quality will continue to be strong as will the administrative input. WRAMC will maintain a high level of involvement that will add to CALGB's overall accrual and scientific endeavors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA026806-12
Application #
3556848
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1979-12-01
Project End
1993-03-31
Budget Start
1991-04-17
Budget End
1992-03-31
Support Year
12
Fiscal Year
1991
Total Cost
Indirect Cost
Name
U.S. Walter Reed Army Med Center
Department
Type
DUNS #
City
Washington
State
DC
Country
United States
Zip Code
20307
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Metzeler, K H; Maharry, K; Kohlschmidt, J et al. (2013) A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia 27:2023-31
Boylan, Alice M; Wang, Xiaofei F; Ko, Richard et al. (2013) Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902. J Thorac Cardiovasc Surg 146:206-11
Grant, Barbara W; Jung, Sin-Ho; Johnson, Jeffrey L et al. (2013) A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer 119:3797-804

Showing the most recent 10 out of 86 publications